Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a clinical trial for the drug selpercatinib in participants with RET-mutant medullary thyroid cancer. The change may reflect new information or developments in the study protocol or outcomes.
    Difference
    0.1%
    Check dated 2024-06-06T14:30:54.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' The new description provides examples of eligibility criteria and includes detailed requirements for participants, such as age, health conditions, and prior treatments.
    Difference
    13%
    Check dated 2024-05-22T21:12:02.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:26:47.000Z thumbnail image

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.